NBTX nanobiotix.com: Enterprise Value to EBITDA Ratio

Brandmark of Nanobiotix S.A. (NBTX)

The use of AI for particle modeling in bioreactors complements the image of Nanobiotix S.A. (NBTX) as a cutting-edge scientific center, which attracts major investors. The Enterprise Value to EBITDA multiple on GURU.Markets summarizes this synergy, where 0.00 represents the latest level. This helps assess the strategy of enhancing radiotherapy through the partnership with Janssen for the global implementation of NBTXR3.

NBTX Nanobiotix Corp: Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/15/2026

Metric breakdowns and analytics for Nanobiotix Corp (NBTX)

- stock price and consensus target price:
Stock Quotes Nanobiotix SA|NBTX - Average Forecast Price
- company stock capitalization data:
Market Valuation Nanobiotix SA|NBTX - Value Adjusted for Debt and Cash
- business book valuation details:
Net Assets per Single Share Nanobiotix|NBTX - Net Asset Value|Market Value to Book Value Ratio nanobiotix.com|NBTX - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Nanobiotix S.A.|NBTX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Nanobiotix|NBTX - Company Cumulative Indebtedness|Debts to Book Capitalization Nanobiotix|NBTX - Long-Term Liabilities|Company Short-Term Debt Nanobiotix|Quick Liquidity nanobiotix.com
- business earnings and investment ratios data:
NBTX - Final Profit|Expected Profit Nanobiotix S.A.|NBTX - Price to Earnings Ratio|Future Price to Earnings Nanobiotix SA|NBTX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nanobiotix Corp|NBTX - Operating profit before amortization|Net earnings per share (EPS TTM) Nanobiotix|NBTX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months nanobiotix.com|NBTX - Earnings per share growth this year|Net earnings per share growth forecast for next year Nanobiotix S.A.
- sales volume and revenue information:
NBTX - Company Total Revenue|Projected Sales Volume Nanobiotix S.A.|NBTX - Price-to-Revenue Ratio|Forward P/S Multiple Nanobiotix Corp|NBTX - Annual Revenue Growth (Last Twelve Months)
General company analysis:Nanobiotix Corp NBTX
Product sample of Nanobiotix SA

The EV/EBITDA multiple determines the real value of a business by excluding the impact of debt load and tax distortions to assess the enterprise's net operating efficiency. By analyzing the current EV/EBITDA level of Nanobiotix S.A. (NBTX), an investor can compare the company's capital expenditures on global oncology clinical trials against the business's generated capacity to timely identify capital impairment risks amid rising borrowings.

Direct competitors

Geron Corp - Enterprise Value to EBITDA Ratio|Bicycle Therapeutics plc (BCYC) - Company Value to EBITDA|CTMX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CATX (Perspective Therapeutics, Inc.)|Genelux (GNLX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio MOLN (molecularpartners.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oncolytics Biotech Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LSTA|EV/EBITDA Multiple MBRX|EV/EBITDA Multiple Galera (GRTX)|Molecular Templates, Inc. - Enterprise Value to EBITDA Ratio